NSAIDs and aspirin: notorious or FAMOUS?

The Lancet

Volumn 374, Issue 9684, 2009, Pages 93-94

  Hawkey, CJ ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DIGESTIVE SYSTEM ULCER; DISEASE COURSE; DRUG SAFETY; DUODENUM ULCER; ERADICATION THERAPY; ESOPHAGITIS; HEALTH ECONOMICS; HEART INFARCTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HEMOSTASIS; HUMAN; LIVER FAILURE; LOW DRUG DOSE; MUCOSAL DISEASE; PEPTIC ULCER; PEPTIC ULCER BLEEDING; POLITICS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; STOMACH ULCER; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 67649865386     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61245-9     Document Type: Note

References (13)

1. Taha A.S., Hudson N., Hawkey C.J., et al. Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N Engl J Med 334 (1996) 1435-1439
2. Bombardier C., Laine L., Reicin A., et al., for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
3. Hawkey C.J., Karrasch J.A., Szczepanski L., et al., for the Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 338 (1998) 727-734
4. Hawkey C.J. Safer NSAID strategies: consensus or contentious?. Rheumatology 47 (2008) 1265-1266
5. Chan F.K., Wong V.W., Suen B.Y., et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 369 (2007) 1621-1626
6. Schnitzer T.J., Burmester G.R., Mysler E., et al., on behalf of the TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research & Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
7. Hawkey C.J., and Langman M.J. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52 (2003) 600-608
8. Information Centre for Health and Social Care. Prescriptions. http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions (accessed July 2, 2009).
9. British National Formulary. 10.1.1: non-steroidal anti-inflammatory drugs (March, 2009), BMJ Group and RPS Publishing, London
10. Taha A.S., McCloskey C., Prasad R., and Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet (2009) 10.1016/S0140-6736(09)61246-0 published online July 6.
11. Labenz J., Tillenburg B., Peitz U., et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 41 (1997) 33-36
12. Yeomans N., Lanas A., Labenz J., et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103 (2008) 2465-2473
13. Chan F.K., Chung S.C., Suen B.Y., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973